Peptide Claims & Evidence

Check a claim about a peptide. Each check gives a plain-English answer first, then the scope, the strongest evidence, what is uncertain, what would change the answer, the date checked and the real review status. Version 1.6.0, checked 2026-11-14.

Review status: AI-assisted source verification. Human review: none recorded. Human review is pending and has not happened. Claim wording shown here is representative, not a quotation. This is not medical advice and not a recommendation for or against any treatment.

12 of 12 claim checks.

  • Overstated

    BPC-157 and tendon healing

    Claim (representative wording): BPC-157 heals torn tendons.

    In animals and cells, BPC-157 has been reported to help tendon healing, with mixed results in the most recent rat study. In the sources and registries WPF searched, no completed controlled human study of tendon healing was found, so a claim that it heals human tendons is not supported.

    Checked 2026-11-15 · Effectiveness · bpc-157 (also searched as BPC 157, Body Protection Compound-157, PL 14736, Bepecin)

  • Insufficient evidence

    BPC-157 and safety in humans

    Claim (representative wording): BPC-157 has been shown to be safe in people.

    WPF found only very small human reports: a two-person intravenous pilot with no adverse effects reported, and a retrospective knee-pain series that reported pain outcomes rather than safety data. That cannot show safety, and the one registered safety trial has no posted results.

    Checked 2026-11-15 · Safety · bpc-157 (also searched as BPC 157, Body Protection Compound-157, Bepecin)

  • Overstated

    SS-31 and aging

    Claim (representative wording): SS-31 (elamipretide) reverses or slows aging in people.

    A single dose improved a short-lived muscle-energy measurement in older adults, but it did not improve fatigue resistance and the effect was gone a week later. That is not evidence that it slows aging.

    Checked 2026-11-14 · Effectiveness · elamipretide (also searched as SS-31, Bendavia, MTP-131, Forzinity)

  • Overstated

    Humanin and longevity

    Claim (representative wording): Humanin extends lifespan.

    In roundworms, genetically increasing humanin extended lifespan. In mice, a humanin analogue started in middle age did not change survival in the one mouse lifespan test WPF found, though it improved some health measures. In people there are associations and no treatment trial.

    Checked 2026-11-16 · Effectiveness · humanin (also searched as HN, HNG, Humanin-G, S14G-humanin)

  • Contradicted by evidence

    A “research use only” label and the products in one FDA warning letter

    Claim (representative wording): A product labelled “research use only” is not a drug.

    For the seven products in FDA's warning letter to Xcel Research LLC, a “for research use only” label did not make them non-drugs. FDA said the seller's own website claims showed the products were intended as drugs for human use, and that they were unapproved new drugs with no approved application in effect. The letter does not say whether using such a product is acceptable or safe, and this check does not either.

    Checked 2026-11-15 · Regulatory status · retatrutide, cagrilintide, semaglutide, mazdutide, survodutide (also searched as RETA, LY3437943, research chemical, RUO, Xcel Research, CagriLean, SEMA)

  • Overstated

    When weight-loss results can be compared

    Claim (representative wording): Tirzepatide caused more weight loss than semaglutide, because its trial showed a bigger percentage.

    Percentages can be compared directly only when both drugs were randomized in the same trial, and WPF found that for one trial in this set (SURMOUNT-5). Two separate placebo-controlled trials differ in people, length and design, so subtracting them proves nothing.

    Checked 2026-11-16 · Study interpretation, Effectiveness · tirzepatide, semaglutide, retatrutide (also searched as Mounjaro, Zepbound, Wegovy, Ozempic)

  • Supported within scope

    Tirzepatide and semaglutide in the same trial

    Claim (representative wording): Tirzepatide and semaglutide have been compared head to head in a randomized trial.

    Yes, in SURMOUNT-5, a 72-week open-label trial in adults with obesity: -20.2% with tirzepatide against -13.7% with semaglutide. Other weight-loss results for the two drugs come from separate trials and cannot be subtracted.

    Checked 2026-11-16 · Study interpretation · tirzepatide, semaglutide (also searched as Mounjaro, Zepbound, Wegovy, Ozempic)

  • Supported within scope

    SS-31 and elamipretide: one compound under several names

    Claim (representative wording): SS-31 and elamipretide are the same substance.

    Public records treat them as one compound: SS-31, MTP-131 and Bendavia are listed as other names for elamipretide. WPF did not compare structures itself.

    Checked 2026-11-14 · Product identity · elamipretide (also searched as SS-31, Bendavia, MTP-131, Forzinity)

  • Overstated

    Trial registration versus posted results

    Claim (representative wording): If a peptide trial is registered, its results are public.

    Trial registration does not guarantee that results will be posted. In WPF’s sample, the completed BPC-157 supplement study NCT07752381 had no results posted on ClinicalTrials.gov as of the review date.

    Checked 2026-11-22 · Study interpretation · bpc-157, elamipretide, semaglutide, tirzepatide (also searched as ClinicalTrials.gov, NCT number)

  • Overstated

    Cell and animal results versus human results

    Claim (representative wording): It worked in cells and mice, so it works in people.

    A good result in cells or animals shows a compound is worth testing in people. It does not show the compound works in people. For elamipretide (SS-31), aged mice showed better muscle energy use and endurance, but in a randomized phase 3 trial in adults with primary mitochondrial myopathy it did not beat placebo on walking distance or fatigue. The mouse work was in aging, not in this disease, so this illustrates the gap and does not show the mouse result was wrong.

    Checked 2026-11-14 · Study interpretation, Effectiveness · elamipretide (also searched as SS-31, Bendavia, MTP-131, MMPOWER-3, mitochondrial myopathy, animal study, mouse study)

  • Overstated

    Evidence for an approved medicine and other products with the same peptide name

    Claim (representative wording): Studies of an approved semaglutide medicine apply automatically to any product called semaglutide.

    The trials behind an approved medicine tested that medicine. Their results carry over to another product only when a regulator has found the two equivalent, which is how an FDA-approved generic is judged against a named reference product. FDA states that compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before they are marketed, so such a product does not inherit the trial evidence through its name.

    Checked 2026-11-14 · Regulatory status, Product identity, Study interpretation · semaglutide, liraglutide (also searched as Wegovy, Ozempic, Victoza, Saxenda, compounded semaglutide, generic liraglutide, salt form)

  • Insufficient evidence

    Evidence on single peptides versus taking them together

    Claim (representative wording): Each of these peptides has evidence behind it, so taking them together must be safe and work.

    Evidence on each peptide alone is not enough to say what happens when they are used together. The one combination checked here, cagrilintide with semaglutide (CagriSema), was tested in a randomized trial against each component and placebo, and the paper's abstract says its efficacy was unknown beforehand. The results apply to that combination in that trial's population and say nothing about other combinations.

    Checked 2026-11-14 · Safety, Effectiveness, Study interpretation · semaglutide, cagrilintide (also searched as CagriSema, REDEFINE 1, REDEFINE 5, combination, stack, taking together)

What the verdicts mean

Supported within scope
The sources WPF read support the claim as worded, for the stated population or organism, design, product and time. Nothing wider is implied.
Overstated
Part of the claim is supported, but the claim says more than the sources show: a wider population, a stronger outcome, a human result from animal work, or a certainty the design cannot give.
Insufficient evidence
The sources WPF read neither support nor contradict the claim. The page states exactly what is missing and where WPF looked.
Contradicted by evidence
A source WPF read states the opposite of the claim, within the claim's scope.

Overstated applies when a claim goes beyond what the relevant evidence supports; Insufficient evidence applies when the evidence is inadequate to answer the specific question being asked.

A verdict applies to the claim as worded, inside its stated scope. It is never a verdict on a peptide as a whole. Where WPF could not resolve a claim, the page says exactly what is missing.

How to cite a check, and what the dates mean

The version (1.6.0) identifies this release of the set of checks, and the date beside it (2026-11-14) is when that release's checks were made. Each check also shows its own “checked” date. A check that was added or re-verified afterwards carries its own, later date, so the dates on individual checks can differ from the release date. A citation names the version and that check's own date, and its record address keeps returning exactly what was checked even after a newer version is published.

Example: the real citation for “SS-31 and aging”

SS-31 and aging: A single dose improved a short-lived muscle-energy measurement in older adults, but it did not improve fatigue resistance and the effect was gone a week later. That is not evidence that it slows aging. Verdict: Overstated. Cited from World Peptide Foundation, Peptide Claims & Evidence, version 1.6.0, claim ss-31-slows-aging, checked 2026-11-14. AI-assisted source verification; human review none recorded.

Page:
https://www.worldpeptidefoundation.org/research/check/ss-31-slows-aging

Versioned record:
https://www.worldpeptidefoundation.org/api/research/claims/ss-31-slows-aging?version=1.6.0

Research journeys · What changed? · Teaching exercise · Methodology